WIN’s Digital Display Precision Predictor biomarker to guide cancer targeted therapy
Posted: Friday, April 30, 2021
WIN Consortium announces publication of the Digital Display Precision Predictor global biomarker prototype for cancer patients in NPJ Precision Oncology
VILLEJUIF, FRANCE, April 30, 2021
The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the
prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698- 021-00171-6).
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic
approach used for most targeted therapies provides limited treatment options, with a binary